Aquestive Therapeutics Inc
AQST
Company Profile
Business description
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Contact
30 Technology Drive
WarrenNJ07059
USAT: +1 908 941-1900
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
142
Stocks News & Analysis
stocks
Goldman Sachs Earnings: Valuations remain stretched
We raise our fair value estimate for Goldman Sachs stock.
stocks
Major ASX listed miners overvalued
We’ve adjusted our fair values after updating our commodity price assumptions.
stocks
Undervalued ASX share with pathway to positive cash flow
Higher sales and a new loan facility increase our conviction.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,195.00 | 12.30 | -0.13% |
| CAC 40 | 8,258.94 | 54.18 | -0.65% |
| DAX 40 | 25,297.13 | 55.26 | -0.22% |
| Dow JONES (US) | 49,359.33 | 83.11 | -0.17% |
| FTSE 100 | 10,235.29 | 3.65 | -0.04% |
| HKSE | 26,844.96 | 78.66 | -0.29% |
| NASDAQ | 23,515.39 | 14.63 | -0.06% |
| Nikkei 225 | 53,255.15 | 681.02 | -1.26% |
| NZX 50 Index | 13,640.53 | 77.57 | -0.57% |
| S&P 500 | 6,940.01 | 4.46 | -0.06% |
| S&P/ASX 200 | 8,875.30 | 8.40 | -0.09% |
| SSE Composite Index | 4,101.91 | 0.00 | -0.00% |